Intuitive Surgical, Inc. (ISRG)
ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency
Intuitive Surgical's Ion platform posted 52% procedure growth in Q2, but rising system utilization and workflow efficiency now drive its profitability focus.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
ISRG's Gross Margin Falls on Product Transition and Trade Pressures
Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
Intuitive Surgical (ISRG) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Intuitive Surgical Crushes Q2 Expectations, So Why No Rally?
The world's second-largest company in the healthcare equipment and supplies industry, Intuitive Surgical NASDAQ: ISRG, just reported Q2 financials. The results were solid, but not enough to move shares higher.
ISRG Stock Gains on Q2 Earnings & Sales Beat, Gross Margin Contracts
Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Intuitive Surgical, Inc. (ISRG) Q2 2025 Earnings Call Transcript
Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q2 2025 Earnings Conference Call July 22, 2025 4:30 PM ET Company Participants David J. Rosa - CEO & Director Jamie E.
Intuitive Surgical (ISRG) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Intuitive Surgical (ISRG) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Intuitive Surgical, Inc. (ISRG) Q2 Earnings and Revenues Top Estimates
Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $2.19 per share, beating the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $1.78 per share a year ago.
Intuitive Surgical: If You're Looking For A Dip To Buy, Get It Now (Rating Upgrade)
Intuitive Surgical's premium valuation is justified by consistent mid-teens growth, a dominant market position, and a resilient razor-and-blade business model. Recent innovations like telesurgery and regulatory approvals further expand the company's total addressable market and reinforce its competitive moat. Risks include potential tariff impacts and capital return missteps, but a strong balance sheet and recurring revenues mitigate these concerns.
ISRG vs. SYK: Which Robotic Surgery Stock Is the Stronger Buy Today?
As robotic-assisted surgery continues its rising adoption in modern medicine, two industry leaders — Intuitive Surgical ISRG and Stryker SYK — are shaping the future of robotic-assisted surgery. Intuitive, renowned for its da Vinci Surgical System, continues to dominate the soft tissue surgery space.
